Since the beginning of 2025, the volume of state purchases of medicines has reached 531.6 billion rubles

According to the company's report, since the beginning of the year, the budget savings rate has averaged 4% (in 2024 - 3.6%). Taking into account the auctions announced at the end of 2024, played out at the beginning of the current year, 308 thousand auctions were held in the seven months for a total of 691.864 billion rubles, of which 178 thousand auctions for 518.39 billion rubles were recognized as valid, another 122 thousand (33%) auctions for 171.94 billion rubles did not take place.

In 2024, during the specified period, 277 thousand trades were conducted for a total amount of 743.855 billion rubles, of which 172 thousand trades for 596.318 billion rubles took place, 95 thousand (25%) trades for 146.262 billion rubles were declared invalid.

The IT company presented data on purchases from a single supplier without announcing tender procedures. In 2025, the volume of such purchases fell in monetary terms by 57% compared to 2024, while their number increased by 16%.

The largest percentage increase in sales of drugs under government contracts compared to January-July 2024 was shown by Gilead Sciences (40%), AbbVie (20%) and Novartis (6%). Similar indicators for the same period decreased for Roche (-44%), Johnson & Johnson (-36%) and AstraZeneca (-13%).

Analysts at Kursor presented the top trade names (TN) that showed the greatest increase in funds. Sodium Chloride (sodium chloride) came in first place with an increase of 158%, followed by Maviret (glecaprevir + pibrentasvir) with an increase of 61%, which is purchased in large volumes by the Federal Center for Planning and Organization of Drug Provision (FCPiLO). In third place is Forsiga (dapagliflozin), its increase was 55%, followed by Perjeta (pertuzumab) - 34% and Kadcyla (trastuzumab emtansine) - 22%.

The main suppliers of drugs in the public procurement segment of medicines remain Pharmstandard, R-Pharm and Irvin - their share is 20% of the market (in 2024, the figure was 27%). Kursor noted that the share of the TOP10 suppliers in the total volume of supplies has decreased even more: from January to July 2025, it amounted to 36% of the market, in 2024, the share was about 45%. Only Protek (82%) and Lancet (34%) showed an increase.

The list of regions with the most significant increase in purchases in 2025 included the Chelyabinsk Region (60%), the Sverdlovsk Region (59%) and the Rostov Region (54%).

In the first seven months of 2025, the Federal Center for the Development of Industrial Policy and Lomonosov Moscow Region announced 442 tenders worth 83.6 billion rubles, 323 contracts worth 65.2 million rubles were concluded. 119 tenders worth 16.5 billion rubles did not take place, which is 20% of the volume of announced tenders. In 2024, for the same period, 904 tenders worth almost 200 billion rubles were announced, 653 contracts worth 174.7 billion rubles were concluded, 251 tenders worth 25.8 billion rubles did not take place (13% of the volume of announced tenders).

Under the program "14 high-cost nosologies" (HCN), in 2025 it was possible to conclude contracts for 23.9 billion rubles (in 2024 - 64.9 billion rubles). In order to ensure the National Immunization Calendar, drugs were purchased for almost 4.276 billion rubles (in 2024 - for 36.189 billion rubles). 15.2 billion rubles were allocated for the purchase of drugs for the state fund "Circle of Good" (in 2024 - 38.5 billion rubles), for the treatment of HIV infection and hepatitis - 21.8 billion rubles (in 2024 - 35 billion rubles).

In mid-June 2025, the Cursor company presented consolidated data on government procurement of medicines from January to May 2025. It was noted that during this period, the volume of purchases decreased by 15% compared to 2024 and amounted to 422.3 billion rubles. The average savings of budget funds increased slightly - from 3.6% in 2024 to 3.8% in 2025.